1 In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion

2 Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus

3 Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group

4 Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus

5 Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

6 Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse

7 Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old

8 An ultrastructural study of the interaction of human eosinophils with respiratory syncytial virus

9 Testing models predicting severity of respiratory syncytial virus infection on the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada

10 Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment

11 Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement

12 Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

13 Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant

14 Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn

15 Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza a and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4

16 Right and left ventricular function in hospitalized children with respiratory syncytial virus infection

17 Right and left ventricular function in hospitalized children with respiratory syncytial virus infection

18 Analytical performances of the BD Veritor™ System for the detection of respiratory syncytial virus and influenzaviruses A and B when used at bedside in the pediatric emergency department.

19 Development of a reverse transcription recombinase polymerase amplification assay for rapid detection of human respiratory syncytial virus.

20 Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze

21 The Changes of Th17/Treg and Related Cytokines: IL-17, IL-23, IL-10, and TGF-β in Respiratory Syncytial Virus Bronchiolitis Rat Model.

22 Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series.

23 Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series

24 Pathogenesis of Respiratory Syncytial Virus Infection in BALB/c Mice Differs Between Intratracheal and Intranasal Inoculation.

25 Epidemic dynamics of respiratory syncytial virus in current and future climates.

26 Correction to: Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts (Medical Microbiology and Immunology, (2018), 207, 2, (105-115), 10.1007/s00430-017-0531-0)

27 Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection.

28 Evaluation of respiratory syncytial virus IgG antibody dynamics in mother-infant pairs cohort.

29 Disease severity of respiratory syncytial virus (RSV) infection correlate to a novel set of five amino acid substitutions in the RSV attachment glycoprotein (G) in China.

30 Multiple Respiratory Syncytial Virus Introductions Into a Neonatal Intensive Care Unit.

31 Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats

32 An outbreak of febrile illness and pneumonia associated with respiratory syncytial virus infection

33 Quantitative shedding patterns of respiratory syncytial virus in infants

34 Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.

35 Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses

36 Transcriptional mapping of human respiratory syncytial virus.

37 The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species.

38 Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.

39 Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo

40 RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA.

41 Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus

42 Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

43 Pathogenesis of Severe Acute Respiratory Infections in the Developing World: Respiratory Syncytial Virus and Parainfluenza Viruses

44 Transcriptional mapping of human respiratory syncytial virus

45 Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

46 Speculation on Pathogenesis in Death from Respiratory Syncytial Virus Infection

47 Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand

48 Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order.

49 Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

50 Activation of human eosinophils in vitro by respiratory syncytial virus

51 Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection

52 Reinfection of mice with respiratory syncytial virus

53 Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.

54 Virus-specific CD8+ T Lymphocytes Downregulate T Helper Cell Type 2 Cytokine Secretion and Pulmonary Eosinophilia during Experimental Murine Respiratory Syncytial Virus Infection

55 Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial

56 Immunity and immunopathology to respiratory syncytial virus. The mouse model

57 Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.

58 Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

59 Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection

60 Epidemiology of respiratory syncytial virus infection among infants and children in Chicago

61 Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview

62 Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein

63 Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus

64 Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

65 Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection

66 Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice

67 Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections

68 Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases

69 Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants

70 Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

71 Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

72 The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins

73 Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus

74 Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

75 Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60

76 EPIDEMIOLOGY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION AMONG INFANTS AND CHILDREN IN CHICAGO

77 Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections

78 Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein.

79 Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection

80 The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species

81 Recombinant superoxide dismutase (SOD) administered by aerosol inhibits respiratory syncytial virus infection in cotton rats

82 Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes

83 Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection.

84 Cytotoxic T-cell response to respiratory syncytial virus in mice.

85 Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies

86 A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

87 Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection

88 Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order

89 Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis

90 Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndrome

91 Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection

92 The immunologic response to infection with respiratory syncytial virus in infants

93 Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein

94 Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus

95 Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion

96 Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

97 Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus

98 Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus

99 Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection

100 The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection

101 Epidemiology of respiratory syncytial virus infection in Washington, D.C. 3. Composite analysis of eleven consecutive yearly epidemics

Keyword Connections

Journals

Research Groups

Bibliographies